Compare Citius Pharmaceuticals Inc (CTXR) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Merck & Co., Inc. — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while Merck & Co., Inc. trades at $124.71 (market cap $298.31B). The key difference: Merck & Co., Inc. is far larger — about 20376.4× Citius Pharmaceuticals Inc's market cap, and Merck & Co., Inc. pays a 2.82% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | MRK | |
|---|---|---|
Market Cap | $14.64M | $298.31B |
Sector | Health | Health |
52-Week High | $1.82 | $129.52 |
52-Week Low | $0.53 | $77.60 |
Enterprise Value | $10.86M | $341.72B |
Dividend Yield | — | 2.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
Merck (MRK) trades at $124.34, showing modest daily gains of 0.25% with a bullish technical outlook supported by moving averages. The company maintains strong profitability with 73.91% gross margins and has beaten earnings expectations in recent quarters. Recent acquisition activity, including the Terns Pharmaceuticals deal announced April 7, 2026, demonstrates strategic pipeline expansion in oncology.
Merck presents a compelling investment case with analyst consensus favoring bullish sentiment (67.57% buy ratings) and a $137.30 price target offering ~10% upside. However, rising debt levels and projected 2026 earnings decline warrant caution. The stock's premium valuation at 34x P/E requires sustained execution to justify current pricing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
